Medical Cannabis Access Programme
Specialised Drugs
Medical Cannabis Access Programme
1.
Information on the MCAP
On 26 June 2019, the Minister for Health signed legislation to allow for the operation of the Medical Cannabis Access Programme (MCAP). This Programme will facilitate access to cannabis-based products for medical use in line with legislation and with the clinical guidance for the scheme.
Cannabis products will only be listed in Schedule 1 of the Regulations once they have been considered as suitable for use under the Medical Cannabis Access Programme.
The Medical Cannabis Access Programme will make it possible for a medical consultant to prescribe a cannabis-based treatment for a patient under his or her care for the following medical conditions, where the patient has failed to respond to standard treatments:
- Spasticity associated with multiple sclerosis
- Intractable nausea and vomiting associated with chemotherapy
- Severe, refractory (treatment-resistant) epilepsy
2.
Useful Resources MCAP
-
Department of Health Information on the MCAP
-
Department of Health – Clinical Guidance on Cannabis for Medical Use
3.
IPU Support Documents
-
IPU Medical Cannabis Info Aug 2023
-
CannEpil Oral Solution Form
-
Tilray Order Form
-
New Account Application form Georgelle
4.
HSE PCRS Circular MCAP
-
HSE PCRS Circular 025/21 Medical Cannabis Access Programme (MCAP)
-
HSE PCRS Circular 025/21 Medical Cannabis Access Programme (MCAP)
-
HSE PCRS Circular 018/22 Medical Cannabis Access Programme (MCAP)
-
HSE PCRS Circular 025/23 Medical Cannabis Access Programme (MCAP)
-
HSE PCRS Circular 005/24 Medical Cannabis Access Programme (MCAP) update
5.
DoH Fee Structure MCAP
6.
Legislation MCAP
-
S.I. No. 262/2019 – Misuse Of Drugs (Prescription And Control Of Supply Of Cannabis For Medical Use) Regulations 2019
-
S.I. No. 281/2019 – Misuse Of Drugs (Designation) (Amendment) Order 2019
-
S.I. No. 282/2019 – Misuse Of Drugs (Amendment) Regulations 2019
-
S.I. No. 583/2019 – Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use)(Amendment) Regulation 2019
-
S.I. No. 649/2019 – Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2019
-
S.I. No. 505/2020 – Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2020
-
S.I. No. 557/2021 – Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2021
-
S.I. No. 327/2022 – Misuse of Drugs (Prescription and Control of Supply of Cannabis For Medical Use) (amendments) Regulation 2022
-
S.I. No. 5/2023 – Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023
-
S.I. No. 200/2023 – Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) (No. 2) Regulations 2023
7.
Cannabis Products
List of MCAP Products as of 1st May 2024
|
Administrative Code |
Product Description |
Pack Size |
Reimbursement Price |
|
46121 |
CannEpil™ Oral Solution (100mg/ml CBD, 5mg/ml THC in MCT oil) |
50ml |
€467.64 |
|
46120 |
CannEpil™ Oral Solution (100mg/ml CBD, 5mg/ml THC in MCT oil) |
30ml |
€280.80 |
|
46122 |
Tilray® THC10:CBD10 Oral Solution (10mg/ml CBD, 10mg/ml THC) |
25ml |
€185.00 |
|
46123 |
Oleo Bedrobinol® dried flower THC 13.5% w/w (THC 135 mg/g) |
5 gram |
€84.67 |
|
46125 |
Oleo Bedrocan® dried flower THC 22% w/w (THC 220 mg/g) |
5 gram |
€84.67 |
|
46133 |
Oleo Genetics 25:1 Cannabis Extract |
30 ml |
€208.62 |
|
41630 |
Oleo Genetics 10:10 Cannabis Extract |
30 ml |
€208.62 |
|
46127 |
*Oleo Panacea Inhaler |
1 |
€76.00 |
|
46128 |
Althea CBD12:THC10 |
50ml |
€327.89 |
|
46129 |
Althea CBD1:THC20 |
50ml |
€327.89 |
*Only 1 device permitted every 24 months.